What do systematic reviews say?

SSRIs or SNRIs vs placebo

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 118 participants
  Low

SSRIs or SNRIs vs placebo

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 128 participants
  Very low

SSRIs or SNRIs vs placebo

The review found no eligible studies for this question.

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

SSRIs or SNRIs vs placebo

It is very uncertain whether SSRIs or SNRIs changes withdrawals due to adverse events compared with placebo (very low certainty).

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  OR 3.72 [0.79, 17.53]
  3 studies · 190 participants
  Very low

SSRIs or SNRIs vs other antidepressants

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 152 participants
  Very low

SSRIs or SNRIs vs other antidepressants

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 152 participants
  Very low

Intervention not reported

• Selective serotonin reuptake inhibitors for premenstrual syndrome 2013 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 1276 participants
  Low

Intervention not reported

• Selective serotonin reuptake inhibitors for premenstrual syndrome 2013 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 457 participants
  Moderate

Intervention not reported

• Selective serotonin reuptake inhibitors for premenstrual syndrome 2013 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 843 participants
  Low

Intervention not reported

• Selective serotonin reuptake inhibitors for premenstrual syndrome 2013 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 657 participants
  Moderate

Intervention not reported

The intervention probably leads to higher low dose SSRI versus placebo Luteal or continuous administration (moderate certainty).

• Selective serotonin reuptake inhibitors for premenstrual syndrome 2013 · Cochrane Headline outcomes only
  OR 1.76 [1.13, 2.75]
  7 studies · 1301 participants
  Moderate

Intervention not reported

The intervention probably leads to higher mod dose SSRI versus placebo Luteal or continuous administration (moderate certainty).

• Selective serotonin reuptake inhibitors for premenstrual syndrome 2013 · Cochrane Headline outcomes only
  OR 2.55 [1.84, 3.53]
  15 studies · 2447 participants
  Moderate

Intervention not reported

The intervention probably leads to higher high dose SSRIs versus placebo Continuous administration (moderate certainty).

• Selective serotonin reuptake inhibitors for premenstrual syndrome 2013 · Cochrane Headline outcomes only
  RR 6.35 [2.88, 14]
  1 study · 231 participants
  Moderate

Fluoxetine vs control at end of treatment,

• Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 5436 participants
  High

Fluoxetine vs control at end of treatment,

Fluoxetine showed no clear difference in independent on modified Rankin score (mRS 0 to 2) (primary analysis) compared with control at end of treatment, (high certainty).

• Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery 2021 · Cochrane Headline outcomes only
  RR 0.98 [0.93, 1.03]
  5 studies · 5926 participants
  High

Fluoxetine vs control at end of treatment,

• Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery 2021 · Cochrane Headline outcomes only
  no estimate extracted
  30 participants
  Low

Fluoxetine vs control at end of treatment,

• Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 5356 participants
  High

Fluoxetine vs control at end of treatment,

Fluoxetine showed no clear difference in death compared with control at end of treatment, (moderate certainty).

• Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery 2021 · Cochrane Headline outcomes only
  RR 1.01 [0.82, 1.24]
  6 studies · 6090 participants
  Moderate

Fluoxetine vs control at end of treatment,

Fluoxetine showed no clear difference in number of seizures compared with control at end of treatment, (moderate certainty).

• Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery 2021 · Cochrane Headline outcomes only
  RR 1.4 [1, 1.98]
  6 studies · 6080 participants
  Moderate

Fluoxetine vs control at end of treatment,

Fluoxetine leads to higher bone fractures compared with control at end of treatment, (high certainty).

• Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery 2021 · Cochrane Headline outcomes only
  RR 2.35 [1.62, 3.41]
  6 studies · 6080 participants
  High